IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 176-200 out of 1275.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

Public Release: 29-Jun-2014
Nature Photonics
Single-pixel 'multiplex' captures elusive terahertz images
In an effort that advances attempts to generate images using terahertz light waves, researchers from Boston College, Duke University and the University of New Mexico report in Nature Photonics that they've developing a single-pixel 'multiplex' device that uses boutique metamaterials to capture images in the terahertz realm, which scientists say could play a crucial role in future medical and security imaging initiatives.
Office of Naval Research, National Science Foundation, DOE/Sandia National Laboratories

Contact: Ed Hayward
ed.hayward@bc.edu
617-552-4826
Boston College

Public Release: 29-Jun-2014
Nature Genetics
A single gene separates aggressive and non-aggressive lymphatic system cancer
For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that doesn't require extensive therapy.
NIH/National Cancer Institute

Contact: Karen Teber
km463@georgetown.edu
Georgetown University Medical Center

Public Release: 28-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 28-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 27-Jun-2014
Pain Medicine
Colon cancer survivors are more likely to have pain in the back and abdomen
Researchers from the University of Granada have discovered that colon cancer survivors are more likely to suffer future lesions related with pain in the back and lower abdomen than healthy individuals of the same gender and age.

Contact: Manuel Arroyo-Morales
marroyo@ugr.es
34-958-248-030
University of Granada

Public Release: 27-Jun-2014
European Journal of Cancer
Genetics dominant risk factor in common cancers
A study of individuals who have been adopted has identified genetics as the dominant risk factor in 'familial' breast, prostate and colorectal cancers.

Contact: Bengt Zöller
bengt.zoller@med.lu.se
46-403-91954
Lund University

Public Release: 27-Jun-2014
Cancer Cell
CNIO researchers discover more than 40 melanoma-specific genes that determine aggressiveness
Researchers from the Spanish National Cancer Research Centre have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.

Contact: Nuria Noriega
nnoriega@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)

Public Release: 27-Jun-2014
Cell Reports
Some aggressive cancers may respond to anti-inflammatory drugs
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.
National Institutes of Health, US Department of Defense

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine

Public Release: 26-Jun-2014
Cancer Cell
Diabolical duo: Known breast cancer gene needs a partner to initiate and spread tumors
A team led by Princeton University researchers has found that a gene known as Metadherin promotes the survival of tumor-initiating cells via the interaction with a second molecule called SND1. The finding could suggest new treatment strategies.
US Department of Defense, National Institutes of Health, Cancer Institute of New Jersey

Contact: Catherine Zandonella
czandone@princeton.edu
609-258-0541
Princeton University

Public Release: 26-Jun-2014
Cancer Epidemiology, Biomarkers & Prevention
Continued use of low-dose aspirin may lower pancreatic cancer risk
The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 26-Jun-2014
Genome Medicine
New test predicts the risk of non-hereditary breast cancer
A simple blood test is currently in development that could help predict the likelihood of a woman developing breast cancer, even in the absence of a high-risk BRCA1 gene mutation, according to research published in the open access journal Genome Medicine.
The Eve Appeal, National Institute for Health Research

Contact: Shane Canning
Shane.Canning@biomedcentral.com
44-020-319-22243
University College London

Public Release: 26-Jun-2014
Journal of Interferon & Cytokine Research
Which interferons best control viral infections?
Respiratory and intestinal infections caused by RNA viruses stimulate infected cells to produce interferons, which can act alone or in combination to block virus replication. Important differences between the presence of IFN receptors on cells and new evidence that specific types of IFNs can control RNA virus infection are explored in a Review article in Journal of Interferon & Cytokine Research.

Contact: Kathryn Ruehle
kruehle@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

Public Release: 26-Jun-2014
Blood
Scientists find potential new use for cancer drug in gene therapy for blood disorders
Scientists working to make gene therapy a reality have solved a major hurdle: bypassing a blood stem cell's natural defenses and insert disease-fighting genes into the cell's genome. In a study led by Associate Professor Bruce Torbett at The Scripps Research Institute, researchers report the drug rapamycin, commonly used to slow cancer growth and prevent organ rejection, enables delivery of a therapeutic dose of genes to blood stem cells while preserving stem cell function.
National Insitutes of Health, Canadian CIHR Doctoral Research Award, California HIV/AIDS Research Program, Center/AIDS Research

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute

Public Release: 26-Jun-2014
Science
New infections cause dormant viruses to reactivate
The famous slogan is 'A diamond is forever,' but that phrase might be better suited to herpes: Unlike most viruses, which succumb to the immune system's attack, herpes remains in the body forever, lying in wait, sometimes reactivating years later.
National Institutes of Health

Contact: April Frawley
afrawley@ufl.edu
352-273-5817
University of Florida

Public Release: 26-Jun-2014
General Hospital Psychiatry
Researchers conduct comprehensive review of treatments for depression in cancer patients
When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide. Antidepressants are commonly prescribed, but the evidence on their efficacy is mixed. The role of antidepressants in treating cancer-related depression has not been rigorously studied. To identify best practice for the treatment of depression in cancer, Dartmouth researchers completed a systematic review and meta-analysis of existing research.

Contact: Robin Dutcher
Robin.Dutcher@hitchcock.org
603-653-9056
The Geisel School of Medicine at Dartmouth

Public Release: 26-Jun-2014
Clinical Cancer Research
Researchers home in on way to predict aggressiveness of oral cancer
Studying mouth cancer in mice, researchers have found a way to predict the aggressiveness of similar tumors in people, an early step toward a diagnostic test that could guide treatment, according to researchers at Washington University School of Medicine in St. Louis.
National Institutes of Health

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine

Public Release: 25-Jun-2014
SIAM Journal on Mathematical Analysis
Using math to analyze movement of cells, organisms, and disease
A few recent SIAM journal papers that use math to analyze movement of organisms and cells and transmission of disease in populations.

Contact: Karthika Muthukumaraswamy
karthika@siam.org
267-350-6383
Society for Industrial and Applied Mathematics

Public Release: 25-Jun-2014
ESMO World Congress on Gastrointestinal Cancer 2014
Annals of Oncology
MM-398 added to standard treatment shows survival benefit in mets pancreatic cancer
Adding the novel MM-398 to standard treatment for metastatic pancreatic cancer patients who have already received gemcitabine improves survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.

Contact: ESMO Press Office
media@esmo.org
European Society for Medical Oncology

Public Release: 25-Jun-2014
Nature
First positive results toward a therapeutic vaccine against brain cancer
A prerequisite to the development of a tumor vaccine is to find protein structures in cancer cells that differ from those of healthy cells. Cancer researchers from Heidelberg have now been able to develop a mutation-specific vaccine targeting a protein that is mutated in brain cancer. In the journal 'Nature,' the researchers report that the vaccine arrested tumor growth in mice.

Contact: Dr. Sibylle Kohlstädt
s.kohlstaedt@dkfz.de
German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)

Public Release: 25-Jun-2014
International Journal of Radiation Oncology Biology Physics
Special edition of the Red Journal highlights the need for radiation oncology services in LMICs
The July 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics, the official scientific journal of the American Society for Radiation Oncology, features a special section of 10 articles focusing on global health and radiation oncology in low- and middle-income countries.

Contact: Brittany Ashcroft
press@astro.org
703-839-7336
American Society for Radiation Oncology

Public Release: 25-Jun-2014
Nature
MicroRNA that blocks bone destruction could offer new therapeutic target for osteoporosis
UT Southwestern cancer researchers have identified a promising molecule that blocks bone destruction and, therefore, could provide a potential therapeutic target for osteoporosis and bone metastases of cancer.

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 24-Jun-2014
ICE/ENDO 2014
New transdermal SARM drug for muscle-wasting offers hope for older cancer patients
Muscle wasting that occurs as a result of cancer negatively impacts the well-being and recovery prospects of millions of patients, particularly the rapidly-growing elderly populations in Western societies. Drugs called selective androgen receptor modulators (SARMs) offer hope for these patients, and a new SARM for transdermal administration is promising excellent efficacy without harming liver function and HDL levels. Results and conclusions were presented Tuesday at the joint meeting of the International Society of Endocrinology and the Endocrine Society: ICE/ENDO 2014 in Chicago.

Contact: Aaron Lohr
alohr@endocrine.org
202-971-3654
The Endocrine Society

Public Release: 24-Jun-2014
Journal of Clinical Investigation
Synthetic triterpenoids show promise in preventing colitis-associated colon cancer
Researchers from Case Western Reserve and Dartmouth universities have shown that a class of small antioxidant molecules carries enormous promise for suppressing colon cancer associated with colitis. These findings, published in an early June edition of the Journal of Clinical Investigation, offer hope that physicians ultimately will be able to reduce dramatically the number of sufferers of this inflammatory bowel disease who go on to develop colon cancer.
National Institutes of Health

Contact: Jeannette Spalding
jeannette.spalding@case.edu
216-368-3004
Case Western Reserve University

Public Release: 24-Jun-2014
Nature
Master regulator of key cancer gene found, offers new drug target
A key cancer-causing gene, responsible for up to 20 percent of cancers, may have a weak spot in its armor, according to new research from the Masonic Cancer Center, University of Minnesota. The partnership of MYC, a gene long linked to cancer, and a non-coding RNA, PVT1, could be the key to understanding how MYC fuels cancer cells. The research is published in the latest issue of the journal Nature.
Masonic Cancer Center University of Minnesota, Sarcoma Fund, American Cancer Society

Contact: Caroline Marin
crmarin@umn.edu
612-624-5680
University of Minnesota Academic Health Center

Public Release: 24-Jun-2014
Nature Scientific Reports
UT Arlington nanoparticles could provide easier route for cell therapy
UT Arlington physics researchers may have developed a way to use laser technology to deliver drug and gene therapy at the cellular level without damaging surrounding tissue. The method eventually could help patients suffering from genetic conditions, cancers and neurological diseases.
National Science Foundation, National Institutes of Health

Contact: Traci Peterson
tpeterso@uta.edu
817-272-9208
University of Texas at Arlington

Showing releases 176-200 out of 1275.

<< < 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 > >>

  Search News Releases

     

 

 

EurekAlert!